On Tuesday, Merus hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 81, up from 76 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they launch their biggest price moves.
While now is not an ideal time to buy shares, see if the stock manages to offer and clear a proper buy point.
Merus reported 0% earnings growth last quarter, while sales growth came in at 236%. Look for the next report on or around Jul. 31.
Merus holds the No. 139 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
